|Budget Amount *help
¥2,860,000 (Direct Cost: ¥2,200,000、Indirect Cost: ¥660,000)
Fiscal Year 2020: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
Fiscal Year 2019: ¥1,430,000 (Direct Cost: ¥1,100,000、Indirect Cost: ¥330,000)
|Outline of Research at the Start
Pulmonary arterial hypertension (PAH) is a fatal disease with a 20% 5-years survival rate without treatment. Importantly, early diagnosis method is very rare in pulmonary hypertension, which is confirmed at the mild stage except in special cases such as family onset, and usually the diagnosis of pulmonary hypertension is confirmed after finally progressed. The purpose of this study is to discover new drugs for pulmonary hypertension with antiproliferative effects on VSMCs from patients with PAH by drug repositioning of existing drugs.